Diagnostic and Prognostic Utility of Plasma p‐tau217 for Alzheimer's Disease in Chinese Elderly: Insights From the SILCODE Study With a Derived Threshold
Open Access
- 22 May 2026
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 33 (5) , e70618
Abstract
Background: Plasma phosphorylated tau 217 (p‐tau217) has emerged as a promising Alzheimer's disease (AD) biomarker, yet its longitudinal associations with neurodegeneration and cognitive decline remain inadequately characterized in Chinese populations, and ethnicity‐specific diagnostic thresholds are lacking for optimal clinical application. Methods: A total of 541 participants (402 cognitively unimpaired [CU]; 139 cognitively impaired [CI]) from the Sino Longitudinal Study on Cognitive Decline (SILCODE) cohort were enrolled. Cross‐sectional and longitudinal associations of plasma p‐tau217 with amyloid‐β (Aβ) pathology, neurodegeneration, and cognition were evaluated. Diagnostic thresholds were derived using receiver operating characteristic analysis, and Cox regression assessed prognostic value for clinical progression. Results: Cross‐sectionally, baseline p‐tau217 was associated with greater Aβ burden, neurodegeneration, and poorer cognition in the whole cohort and CI group; in the CU group, associations were confined to amyloid measures. Longitudinally, accelerated p‐tau217 accumulation was associated with faster neurodegeneration and cognitive decline in the whole cohort, with stage‐dependent patterns: nominal associations with neurodegenerative markers in CU and prominent cognitive associations in CI. Plasma p‐tau217 demonstrated high diagnostic accuracy for amyloid positivity (AUC = 0.891; cutoff: 0.529 pg/mL). Threshold‐based stratification effectively differentiated individuals by Aβ burden, neurodegeneration, and cognitive trajectories. Elevated baseline p‐tau217 predicted higher progression risk (Whole cohort: HR = 2.66 [1.28–5.53], p = 0.009; CU: HR = 2.44 [1.07–5.59], p = 0.034). Conclusion: Plasma p‐tau217 serves as a valuable diagnostic and prognostic biomarker for AD, even among CU individuals, and the ethnicity‐specific threshold of 0.529 pg/mL enhances its clinical applicability for early detection and risk stratification in Chinese populations.Keywords
Funding Information
- National Natural Science Foundation of China (82327809)
This publication has 33 references indexed in Scilit:
- Temporal Dynamics and Biological Variability of Alzheimer BiomarkersJAMA Neurology, 2025
- Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker‐guided diagnosticsAlzheimer's & Dementia, 2025
- Plasma p‐tau217 and p‐tau217/Aβ1‐42 are effective biomarkers for identifying CSF‐ and PET imaging‐diagnosed Alzheimer's disease: Insights for research and clinical practiceAlzheimer's & Dementia, 2025
- Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular diseaseAlzheimer's & Dementia, 2025
- Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathologyAlzheimer's & Dementia, 2024
- Significance of plasma p‐tau217 in predicting long‐term dementia risk in older community residents: Insights from machine learning approachesAlzheimer's & Dementia, 2024
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJAMA Neurology, 2023
- Global estimates on the number of persons across the Alzheimer's disease continuumAlzheimer's & Dementia, 2022